Looking for winners in geographic atrophy
NGM’s NGM621 now looks like a dead end, but there are plenty of others hoping for a piece of this market, including Roche and Lineage.
The other shoe drops for Immunic
Failure of a vital catalyst in psoriasis leaves Immunic’s approach at risk of obsolescence.
Kinnate is the latest Raf player to trip up
The company’s attempt to segment Braf-mutant cancers further isn’t going smoothly.
Fourth-quarter data for the little guys
Relmada, Albireo and Mirum prepare for important clinical results, as Intercept is set back again.
Esmo 2022 – Regeneron stakes its Lag3 claim
Fianlimab maintains its leading activity, but more Opdualag competition is not far behind.
ESC 2022 – so far so similar for Farxiga and Jardiance
Astrazeneca’s SGLT2 matches Lilly and Boehringer’s rival in heart failure with preserved ejection fraction, but the big battle could be uptake.
